Vancouver-based Aspect Biosystems and Novo Nordisk have expanded their partnership to accelerate the development of advanced cellular medicines for diabetes. Building on a collaboration launched in 2023, the new agreement gives Aspect rights to key stem cell–derived islet and hypoimmune cell engineering technologies, with Aspect leading development, manufacturing, and commercialization.
Novo Nordisk will make an additional equity investment, provide research funding, and retain options for later-stage participation, as well as eligibility for milestones and royalties. The partnership integrates U.S. and Danish capabilities into Aspect’s Canada-anchored platform, strengthening its end-to-end cell therapy development efforts.
Want to know more? Check out the source code on Techcouver.com.